Amebiasis is one of the world's most common parasitic infections. Each year, approximately 50 million people become infected with amebiasis, and it causes over 100,000 deaths worldwide.1
Although anyone can get amebiasis, the disease is most common among residents of developing countries that have poor sanitation.2 Infection rates are higher in Mexico, India, and tropical regions of Africa, Central America, and Southeast Asia than in other parts of the world.3,4
Amebiasis is rare in the United States, with fewer than 3,000 cases recorded in 1994 (the most recent year that the disease was reported nationally).5 When found, amebiasis is more common among residents who have traveled or lived in developing countries, those who live in institutions with poor sanitary conditions, and homosexual men.2
- Learn more about amebiasis:
- Cause and Risk Factors»
- Signs and Symptoms»
- Tests and Diagnosis»
- Treatment of Amebiasis»
Important Safety Information
WARNING: POTENTIAL RISK FOR CARCINOGENICITY
Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Its use should be reserved for the conditions described in INDICATIONS AND USAGE.
Contraindications
- Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives
- First trimester of pregnancy
- Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose
Warnings and Precautions
- Seizures and neuropathy have been reported. Discontinue Tindamax if abnormal neurologic signs develop
- Vaginal candidiasis may develop with Tindamax and require treatment with an antifungal agent
- Use Tindamax with caution in patients with blood dyscrasias. Tindamax may produce transient leukopenia and neutropenia
Adverse Reactions
Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation. To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.
Please see full Prescribing Information
- Bercu TE, Petri WA, Behm JW. Amebic colitis: new insights into pathogenesis and treatment. Curr Gastroenterol Rep. 2007 Oct;9(5):429-33.
- Amebiasis [Internet]. CDC; 2004 Jan [accessed 2008 Jul 10]. Available from: http://www.cdc.gov/ncidod/dpd/parasites/amebiasis/factsht_amebiasis.htm
- Salles JM, Moraes LA, Salles MC. Hepatic amebiasis. Braz J Infect Dis. 2003 Apr;7(2):96-110. Epub 2003 Nov 19.
- van Hal SJ, Stark DJ, Fotedar R, Marriott D, Ellis JT, Harkness JL. Amoebiasis: current status in Australia. Med J Aust. 2007 Apr 16;186(8):412-6.
- Summary of Notifiable Diseases, United States, 1994 [Internet]. CDC; 1995 Oct 06 [accessed 2008 Jul 16]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00039679.htm
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
